Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Net Margin (2016 - 2025)

China Pharma Holdings' Net Margin history spans 16 years, with the latest figure at 99.68% for Q4 2025.

  • For Q4 2025, Net Margin rose 829.0% year-over-year to 99.68%; the TTM value through Dec 2025 reached 76.91%, up 2767.0%, while the annual FY2025 figure was 76.91%, 2767.0% up from the prior year.
  • Net Margin reached 99.68% in Q4 2025 per CPHI's latest filing, down from 86.15% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 24.28% in Q1 2023 to a low of 155.48% in Q2 2024.
  • Average Net Margin over 5 years is 63.26%, with a median of 54.54% recorded in 2023.
  • Peak YoY movement for Net Margin: plummeted -10147bps in 2024, then skyrocketed 10397bps in 2025.
  • A 5-year view of Net Margin shows it stood at 33.94% in 2021, then dropped by -28bps to 43.28% in 2022, then plummeted by -32bps to 57.32% in 2023, then plummeted by -88bps to 107.98% in 2024, then rose by 8bps to 99.68% in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Net Margin are 99.68% (Q4 2025), 86.15% (Q3 2025), and 51.51% (Q2 2025).